Clinical Trial Update: Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing short infusion versus fixed-dose administration of cisplatin plus gemcitabine in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small-Cell Lung Carcinoma | Phase 2 | Status: COMPLETED